A new era of drug development which is all set to make it better, faster, and affordable by way of biology-driven artificial intelligence is on the cards.
As big pharma continue to outsource their tasks to CROs, the latter needs to have an access to pharmacovigilance automation that helps them with huge benefits.
Big Pharma looks to invest in next-gen labs to boost processes, build necessary capabilities for lab transformation, expedite digitalization, and leverage AI.
By way of automation as well as integration, the SDG 2030 agenda by the UN for the healthcare and diagnostic sectors looks forward to innovate lab procedures.
Researchers are most likely going to accurately evaluate the capabilities and performance of self-driving labs according to the newly recommended criteria.
